We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
Read MoreHide Full Article
Key Takeaways
ISRG raised 2026 procedure growth outlook to 13.5-15.5% as adoption accelerates.
Intuitive Surgical posted 23% Q1 revenue growth, with recurring revenues now at 86% of sales.
ZBH is expanding robotics with ROSA and mBos, but growth remains slower than peers.
The surgical robotics market remains one of the fastest-growing segments within the MedTech industry, and both Intuitive Surgical (ISRG - Free Report) and Zimmer Biomet (ZBH - Free Report) are investing aggressively to capture long-term growth. Intuitive Surgical continues to dominate robotic-assisted surgery through its expansive da Vinci ecosystem, while Zimmer Biomet is building momentum in orthopedic robotics with ROSA and next-generation autonomous robotic systems.
Although ISRG has lost 28.8% year to date compared with ZBH’s modest 2.6% decline, the long-term growth outlook appears more favorable for Intuitive, particularly as innovation and procedure growth continue accelerating into the remainder of 2026.
Both companies enter the second half of 2026 with meaningful catalysts ahead. ISRG recently raised its full-year procedure growth outlook to 13.5-15.5%, reflecting confidence in continued adoption of da Vinci 5, Ion, and SP platforms.
Zimmer Biomet reaffirmed revenue growth guidance of 1-3% while raising EPS expectations to $8.40-$8.55 as its commercial transformation and robotics investments begin to show early progress. While both companies remain innovation-driven, Intuitive Surgical’s stronger growth trajectory continues to stand out.
YTD Price Chart ISRG vs ZBH
Image Source: Zacks Investment Research
Case for ISRG
Intuitive Surgical’s greatest strength lies in its unmatched leadership in robotic-assisted surgery and its highly scalable recurring revenue model. In the first quarter of 2026, revenues surged 23% to $2.77 billion, significantly outpacing the company’s 17% procedure growth — an indication that innovation is driving pricing power and improving monetization.
Recurring revenues grew 23% to $2.4 billion and now accounts for 86% of total revenues, providing exceptional earnings visibility. The continued rollout of da Vinci 5, which now has nearly 1,500 installed systems globally, remains a key driver of future growth.
Beyond core robotic surgery, ISRG continues expanding into high-growth adjacencies. Ion procedures grew 39%, while SP procedures jumped 68%, reflecting broader adoption across lung biopsy and minimally invasive specialty procedures. The company is also aggressively building AI-enabled capabilities around force feedback, digital surgery, telepresence, augmented dexterity, and future automation, strengthening its long-term competitive moat.
Challenges remain in China and Japan due to tender weakness and pricing pressure, but management’s raised outlook suggests confidence that these headwinds remain manageable. With a Zacks Rank #2 (Buy) and stronger earnings momentum, ISRG remains well positioned for the rest of 2026.
ISRG’s Sales Estimate
Image Source: Zacks Investment Research
Case for ZBH
Zimmer Biomet’s core strength lies in its orthopedic robotics strategy and broader diversification across implants, technology, and surgical solutions. In the first quarter of 2026, the company delivered organic revenue growth of 2.9% and adjusted EPS growth of 15.5%, driven by strong adoption of ROSA robotics, TMINI systems, AI-enabled hip navigation through OrthoGrid, and accelerating shoulder and upper-extremity businesses. Technology and data-driven solutions grew nearly 12%, while robotic sales continued expanding at double-digit rates.
The company’s future growth strategy centers on its autonomous robotic platform mBos, acquired through Monogram, which management expects to launch in a semi-autonomous form in early 2027. Additional growth drivers include the Paragon 28 acquisition, expanding digital orthopedic ecosystems, and increasing investments in AI-enabled robotics.
However, near-term challenges remain meaningful. The company continues to navigate disruption from its large U.S. sales force transformation, ongoing pricing pressure in legacy knee implants, modest international growth, and a slower overall revenue growth profile compared with Intuitive Surgical. While ZBH remains a stable operator, its Zacks Rank #3 (Hold) reflects a comparatively more measured upside outlook.
ZBH’s Sales Estimate
Image Source: Zacks Investment Research
Valuation Comparison
ISRG trades at a premium, but this valuation is supported by sustained double-digit growth, expanding global adoption, and a long runway in minimally invasive surgery. Its performance demonstrates resilience despite external pressures, such as tariffs. The company currently trades at a forward 12-month P/E multiple of 36.56X, well above the industry average of 23.71X, and carries a Value Score of D.
ISRG’s P/E F12M Chart
Image Source: Zacks Investment Research
ZBH offers a more balanced risk profile, with dependable earnings growth and margin expansion driven by operational discipline. Its upside potential appears comparatively constrained, given its mature and diversified business mix. The company currently trades at P/E F12M ratio of 10.08X, below the industry average of 15.2X. ZBH carries a Value Score of B.
ZBH’s P/E F12M Chart
Image Source: Zacks Investment Research
Conclusion
Both Intuitive Surgical and Zimmer Biomet are positioning themselves to benefit from the long-term adoption of robotic-assisted surgery, but their growth trajectories differ considerably. Zimmer Biomet offers steady execution, expanding orthopedic robotics exposure, and promising long-term innovation through autonomous surgery platforms.
Intuitive Surgical continues to offer a strong investment case currently. Its superior revenue growth, expanding recurring revenue model, aggressive AI integration strategy, and dominant installed base create a significantly stronger long-term growth narrative. Despite stock underperformance this year compared to ZBH, ISRG’s accelerating innovation pipeline makes it the better robotic surgery stock to own right now.
View the Zacks #1 Rank List
Image: Bigstock
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
Key Takeaways
The surgical robotics market remains one of the fastest-growing segments within the MedTech industry, and both Intuitive Surgical (ISRG - Free Report) and Zimmer Biomet (ZBH - Free Report) are investing aggressively to capture long-term growth. Intuitive Surgical continues to dominate robotic-assisted surgery through its expansive da Vinci ecosystem, while Zimmer Biomet is building momentum in orthopedic robotics with ROSA and next-generation autonomous robotic systems.
Although ISRG has lost 28.8% year to date compared with ZBH’s modest 2.6% decline, the long-term growth outlook appears more favorable for Intuitive, particularly as innovation and procedure growth continue accelerating into the remainder of 2026.
Both companies enter the second half of 2026 with meaningful catalysts ahead. ISRG recently raised its full-year procedure growth outlook to 13.5-15.5%, reflecting confidence in continued adoption of da Vinci 5, Ion, and SP platforms.
Zimmer Biomet reaffirmed revenue growth guidance of 1-3% while raising EPS expectations to $8.40-$8.55 as its commercial transformation and robotics investments begin to show early progress. While both companies remain innovation-driven, Intuitive Surgical’s stronger growth trajectory continues to stand out.
YTD Price Chart ISRG vs ZBH
Image Source: Zacks Investment Research
Case for ISRG
Intuitive Surgical’s greatest strength lies in its unmatched leadership in robotic-assisted surgery and its highly scalable recurring revenue model. In the first quarter of 2026, revenues surged 23% to $2.77 billion, significantly outpacing the company’s 17% procedure growth — an indication that innovation is driving pricing power and improving monetization.
Recurring revenues grew 23% to $2.4 billion and now accounts for 86% of total revenues, providing exceptional earnings visibility. The continued rollout of da Vinci 5, which now has nearly 1,500 installed systems globally, remains a key driver of future growth.
Beyond core robotic surgery, ISRG continues expanding into high-growth adjacencies. Ion procedures grew 39%, while SP procedures jumped 68%, reflecting broader adoption across lung biopsy and minimally invasive specialty procedures. The company is also aggressively building AI-enabled capabilities around force feedback, digital surgery, telepresence, augmented dexterity, and future automation, strengthening its long-term competitive moat.
Challenges remain in China and Japan due to tender weakness and pricing pressure, but management’s raised outlook suggests confidence that these headwinds remain manageable. With a Zacks Rank #2 (Buy) and stronger earnings momentum, ISRG remains well positioned for the rest of 2026.
ISRG’s Sales Estimate
Image Source: Zacks Investment Research
Case for ZBH
Zimmer Biomet’s core strength lies in its orthopedic robotics strategy and broader diversification across implants, technology, and surgical solutions. In the first quarter of 2026, the company delivered organic revenue growth of 2.9% and adjusted EPS growth of 15.5%, driven by strong adoption of ROSA robotics, TMINI systems, AI-enabled hip navigation through OrthoGrid, and accelerating shoulder and upper-extremity businesses. Technology and data-driven solutions grew nearly 12%, while robotic sales continued expanding at double-digit rates.
The company’s future growth strategy centers on its autonomous robotic platform mBos, acquired through Monogram, which management expects to launch in a semi-autonomous form in early 2027. Additional growth drivers include the Paragon 28 acquisition, expanding digital orthopedic ecosystems, and increasing investments in AI-enabled robotics.
However, near-term challenges remain meaningful. The company continues to navigate disruption from its large U.S. sales force transformation, ongoing pricing pressure in legacy knee implants, modest international growth, and a slower overall revenue growth profile compared with Intuitive Surgical. While ZBH remains a stable operator, its Zacks Rank #3 (Hold) reflects a comparatively more measured upside outlook.
ZBH’s Sales Estimate
Image Source: Zacks Investment Research
Valuation Comparison
ISRG trades at a premium, but this valuation is supported by sustained double-digit growth, expanding global adoption, and a long runway in minimally invasive surgery. Its performance demonstrates resilience despite external pressures, such as tariffs. The company currently trades at a forward 12-month P/E multiple of 36.56X, well above the industry average of 23.71X, and carries a Value Score of D.
ISRG’s P/E F12M Chart
Image Source: Zacks Investment Research
ZBH offers a more balanced risk profile, with dependable earnings growth and margin expansion driven by operational discipline. Its upside potential appears comparatively constrained, given its mature and diversified business mix. The company currently trades at P/E F12M ratio of 10.08X, below the industry average of 15.2X. ZBH carries a Value Score of B.
ZBH’s P/E F12M Chart
Image Source: Zacks Investment Research
Conclusion
Both Intuitive Surgical and Zimmer Biomet are positioning themselves to benefit from the long-term adoption of robotic-assisted surgery, but their growth trajectories differ considerably. Zimmer Biomet offers steady execution, expanding orthopedic robotics exposure, and promising long-term innovation through autonomous surgery platforms.
Intuitive Surgical continues to offer a strong investment case currently. Its superior revenue growth, expanding recurring revenue model, aggressive AI integration strategy, and dominant installed base create a significantly stronger long-term growth narrative. Despite stock underperformance this year compared to ZBH, ISRG’s accelerating innovation pipeline makes it the better robotic surgery stock to own right now.